1. Home
  2. MIRM vs HLMN Comparison

MIRM vs HLMN Comparison

Compare MIRM & HLMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • HLMN
  • Stock Information
  • Founded
  • MIRM 2018
  • HLMN 1964
  • Country
  • MIRM United States
  • HLMN United States
  • Employees
  • MIRM N/A
  • HLMN N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • HLMN Industrial Machinery/Components
  • Sector
  • MIRM Health Care
  • HLMN Consumer Discretionary
  • Exchange
  • MIRM Nasdaq
  • HLMN Nasdaq
  • Market Cap
  • MIRM 1.9B
  • HLMN 2.2B
  • IPO Year
  • MIRM 2019
  • HLMN N/A
  • Fundamental
  • Price
  • MIRM $39.10
  • HLMN $7.63
  • Analyst Decision
  • MIRM Strong Buy
  • HLMN Buy
  • Analyst Count
  • MIRM 11
  • HLMN 5
  • Target Price
  • MIRM $58.55
  • HLMN $11.50
  • AVG Volume (30 Days)
  • MIRM 476.2K
  • HLMN 1.7M
  • Earning Date
  • MIRM 05-07-2025
  • HLMN 04-29-2025
  • Dividend Yield
  • MIRM N/A
  • HLMN N/A
  • EPS Growth
  • MIRM N/A
  • HLMN N/A
  • EPS
  • MIRM N/A
  • HLMN 0.09
  • Revenue
  • MIRM $336,888,000.00
  • HLMN $1,472,595,000.00
  • Revenue This Year
  • MIRM $29.51
  • HLMN $5.94
  • Revenue Next Year
  • MIRM $20.27
  • HLMN $4.49
  • P/E Ratio
  • MIRM N/A
  • HLMN $86.72
  • Revenue Growth
  • MIRM 80.76
  • HLMN N/A
  • 52 Week Low
  • MIRM $23.14
  • HLMN $7.24
  • 52 Week High
  • MIRM $54.23
  • HLMN $12.08
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 34.64
  • HLMN 35.46
  • Support Level
  • MIRM $37.83
  • HLMN $7.43
  • Resistance Level
  • MIRM $40.32
  • HLMN $7.93
  • Average True Range (ATR)
  • MIRM 2.47
  • HLMN 0.42
  • MACD
  • MIRM -0.33
  • HLMN -0.02
  • Stochastic Oscillator
  • MIRM 25.14
  • HLMN 21.91

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About HLMN Hillman Solutions Corp.

Hillman Solutions Corp is a provider of hardware-related products and related merchandising services to retail markets in North America. The company sells its products to hardware stores, home centers, mass merchants, pet supply stores, and other retail outlets. Its product lines include thousands of small parts such as fasteners and related hardware items; threaded rod and metal shapes; keys and accessories; builder's hardware; personal protective equipment, such as gloves and eye-wear; and identification items, such as tags and letters, numbers, and signs. The segments of the group are Hardware and Protective Solutions, which is the key revenue-generating segment; Robotics and Digital Solutions; and Canada. It has a business presence in the US, Canada and Mexico.

Share on Social Networks: